Drugs / Measles, mumps, and rubella vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06693895 Background | Nov 2024 → Nov 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps, and rubella vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06693895 ↗ |
| Modality | Vaccine | “measles, mumps, and rubella vaccine” NCT06693895 ↗ |
| Route | Intramuscular | “co-administered subcutaneously or intramuscularly” NCT06693895 ↗ |
| Route | Subcutaneous | “co-administered subcutaneously or intramuscularly” NCT06693895 ↗ |